Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trial

Pharmacology, Toxicology and Pharmaceutical Science

• Atrial Fibrillation 100%
• Bleeding 100%
• Anticoagulant Agent 100%
• Artery Embolism 100%
• Heart Infarction 50%
• Brain Ischemia 50%
• Venous Thromboembolism 50%
• Randomized Controlled Trial 50%
• All Cause Mortality 50%
• Cardiovascular Mortality 50%
• Cerebrovascular Accident 50%

Keyphrases

• Anticoagulant Therapy 100%
• Oral Anticoagulation 100%
• Left Atrial Appendage Closure 100%
• Percutaneous Left Atrial Appendage Closure 42%
• Atrial Fibrillation 28%
• Acute Arterial Embolism 28%
• Myocardial Infarction 14%
• Cardiovascular Mortality 14%
• Ischemic Stroke 14%
• Stroke Risk 14%
• Cardiac Surgery 14%
• Venous Thromboembolism 14%
• Randomized Trial 14%
• Hospitalization 14%
• Bleeding 14%
• Bleeding Risk 14%
• Major Bleeding 14%
• All-cause Mortality 14%
• Blood Transfusion 14%
• First Occurrence 14%
• Multicenter Randomized Controlled Trial 14%
• Expected Mean 14%
• Trial Testing 14%
• Quality of Life Measures 14%
• Cardiac CT 14%

Medicine and Dentistry

• Anticoagulant Therapy 100%
• Anticoagulation 100%
• Oral 100%
• Atrial Fibrillation 28%
• Arterial Embolism 28%
• Myocardial Infarction 14%
• Heart Surgery 14%
• Bleeding 14%
• Venous Thromboembolism 14%
• Randomized Controlled Trial 14%
• Apoplexy 14%
• Major Bleeding 14%
• Brain Ischemia 14%
• All Cause Mortality 14%
• Blood Transfusion 14%
• Cardiovascular Mortality 14%
• Quality of Life Measure 14%
• X-Ray Computed Tomography 14%